Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases |
Ouda, SM
(Department of Microbiology & Immunology, Faculty of Medicine, Cairo University)
Khairy, AM (Department of Endemic Medicine, Faculty of Medicine, Cairo University) Sorour, Ashraf E (Department of Microbiology & Immunology, Faculty of Medicine, Cairo University) Mikhail, Mikhail Nasr (Department of Microbiology & Immunology, Faculty of Medicine, Cairo University) |
1 | Agha S, Tanaka Y, Saudy N, et al (2004). Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan. J Med Virol, 73, 216-22. DOI |
2 | Ancha Baranova, Priyanka Lal, Aybike Birerdinc, Zobair M Younossi (2011). Non-Invasive markers for hepatic fibrosis. Gastroenterol, 11, 91. |
3 | Asanza Cilia G, Carmelo Garcia A-Monezo, Gerardo Clement, et al (1997). Immunohistochemical evidence of immunopathogenetic mechanisms in Chronic Hepatitis C Recurrence After Liver Transplantation. Hepatol, 26, 755-63. DOI |
4 | Behne Tara and Sitki M. Copur (2012). Biomarkers for Hepatocellular Carcinoma. Int J Hepatol, 859076. |
5 | Changhoon Yoo, Dok Hyun Yoon, Shinkyo Yoon, et al (2015). Prognostic impact of 2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. Leukaemia Lymphoma, 56, 688-93. DOI |
6 | Chatterjeea Reshmi and Mitra Abhisek (2015). An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol, 24, 335-45. DOI |
7 | Chung Raymond T., and Baumert F (2014). Curing chronic hepatitis c. the arc of a medical triumph. N Engl J Med, 370, 1576-8. DOI |
8 | Cuadros Diego F, Branscum Adam J, Miller F. DeWolfe, Abu- Raddad Laith J (2014). Spatial epidemiology of hepatitis C virus infection in Egypt: Analyses and implications. Hepatol, 60, 1150-9. DOI |
9 | ELGendy Saad M, Mohamed Hessien, Mahmoud M. EL Sherbiny (2005). A panel of molecular markers in hepatitis c virus-related hepatocellular carcinoma. J Egyptian Nat Cancer Inst, 17, 270-8. |
10 | Feld Jordan J, Kowdley Kris V, Coakley Eoin, et al (2014). Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med, 370, 1594-603. DOI |
11 | Flemming Jennifer A, Ju Dong Yang, Eric Vittinghoff, W. Ray Kim, Norah A (2014). Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The Adress HCC risk model. Terrault Cancer, 120, 3485-93. DOI |
12 | Hajarizadeh Behzad, Jason Grebely, Gregory J. Dore (2013). Epidemiology and natural history of HCV infection. Nature Rev Gastroenterol Hepatol, 10, 553-62. DOI |
13 | Hamidreza Abdolsamadi, Peiman Eini , Kieslichova E, et al. (2013). Evaluation of salivary beta-2 microglobulin as HBV proliferation marker in HBS Ag+, HBV DNA PCR+ and HBV DNA PCR- subjects. J Gastroenterol Hepatol, 6, 105-11. |
14 | Huang J (2002). HLA in hepatocellular carcinoma. World J Gastroenterol, 8, 1007-9327. |
15 | Huckans Marilyn, Bret E. Fuller, Hannah Olavarria, et al (2014). Altered expression of peripheral immune factors is associated with neuro-psychiatric symptom severity in adults with and without chronic hepatitis C virus infection. Brain Behavior, 4, 123-42. DOI |
16 | Kanwal Fasiha, Bacon Bruce R (2012). Does treatment alter the natural history of chronic HCV? Chronic Hepatitis C Virus, 103-12. |
17 | Khalid SS, Hamid S, Siddiqui AA, Qureshi A, Qureshi N (2011). Gene profiling of early and advanced liver disease in chronic hepatitis C patient. J Hepatol Int, 5, 782-8. DOI |
18 | Kim JW, Wang XW (2003). Gene expression profiling of preneoplastic liver diseases and liver cancer. A new era for early detection and treatment of these deadly diseases. Carcinogenesis, 24, 363-9. DOI |
19 | Malaguarnera M, Di Fazio I, Ferlito L (2000). Increase of serum beta 2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 12, 937-9. DOI |
20 | Migliaresia Sergio, Alessandro Bresciania, Luci Ambrosone, et al (2000). Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemia. Ann Rheum Dis, 59, 20-5. DOI |
21 | Mourad Wesam, Basuni Ashraf, Fouad Tarekb, et al (2013). The value of PIVKA-II and AFP-L3% in the diagnosis of hepatocellular carcinoma with normal and abnormal AFP levels. Egypt Liver J, 3, 1-5. DOI |
22 | Quiroga J, Martin J, Pardo M, Carreno V (1994). Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferonalpha. Dig Dis Sci, 39, 2485-96 DOI |
23 | Riolobos Laura, Hirata Roli K, Turtle Cameron J, et al (2013). HLA engineering of human pluripotent stem cells. Molecular Therapy, 21, 1232-41. DOI |
24 | Saito Yumi , Nobukui Oba, Syuta Nishinakagawa, et al (2010). Identification of 2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis. Oncol Reports, 23, 1325-30. |
25 | Saleh M (2012). Study the expression level of beta 2 microglobulin gene on hepatitis C patients before and after treatment with Interferon. Baghdad Sci J, 9, 504-10. |
26 | Tabayoyong William B. and Zavazava Nicholas (2007). Soluble HLA revisited. Leuk Res, 31, 121-5. DOI |
27 | Ward DG, Cheng Y, N'Kontchou G, et al (2006). Preclinical and post-treatment changes in the HCC-associated serum proteome. British J Cancer, 95, 1379-83. DOI |